© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
September 04, 2020
Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.
September 01, 2020
The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.
Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.
Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.
August 27, 2020
Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.
Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.